Kratom (Mitragyna speciosa)

Kratom (Mitragyna speciosa) contains mitragynine and 7-hydroxymitragynine alkaloids that act as partial mu-opioid receptor agonists. These compounds produce analgesic and stimulant effects depending on dosage and strain composition.

Origin & History

Kratom (Mitragyna speciosa) is a tropical evergreen tree native to Southeast Asia, particularly Thailand, Malaysia, Indonesia, and Papua New Guinea. The leaves are harvested, dried, and processed using organic solvents like acetone or alcohols to extract alkaloids, as the primary compound mitragynine is insoluble in water.

Historical & Cultural Context

In Southeast Asian traditional medicine systems of Thailand and Malaysia, kratom leaves have been chewed or brewed as tea for centuries to boost energy, relieve pain, and manage various conditions. Documented use dates back nearly 100 years in studies, though traditional practice is considerably older.

Health Benefits

• Pain management potential based on mu-opioid receptor partial agonism (preclinical evidence only)
• Energy enhancement as documented in traditional Southeast Asian use (traditional evidence)
• Opioid withdrawal symptom management (traditional use, no clinical trials)
• Anti-fatigue effects reported in ethnomedicine practices (traditional evidence only)
• Anti-diarrheal properties in folk medicine applications (traditional use, lacking clinical validation)

How It Works

Mitragynine and 7-hydroxymitragynine function as partial agonists at mu-opioid receptors while also interacting with adrenergic and serotonergic pathways. At lower doses, adrenergic stimulation predominates, producing stimulant effects, while higher doses favor opioid receptor activation for analgesic effects. The alkaloids also modulate dopamine and GABA neurotransmitter systems.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses have been conducted on kratom. All current evidence is limited to preclinical studies and traditional use reports, with sources explicitly noting insufficient evidence for clinical use in humans.

Clinical Summary

Clinical evidence for kratom remains extremely limited with no large-scale randomized controlled trials published. Small observational studies and case reports suggest potential for pain management and opioid withdrawal symptom relief, but sample sizes are typically under 50 participants. Most evidence comes from traditional use documentation and preclinical animal studies rather than human clinical trials. Current research focuses primarily on safety profiles and abuse potential rather than therapeutic efficacy.

Nutritional Profile

{"macronutrients": {"protein": "1-2% by weight", "fiber": "2-3% by weight"}, "micronutrients": {"calcium": "80-100 mg per 100g", "magnesium": "40-60 mg per 100g", "potassium": "30-50 mg per 100g"}, "bioactive_compounds": {"mitragynine": "up to 66% of total alkaloid content", "7-hydroxymitragynine": "up to 2% of total alkaloid content", "speciogynine": "up to 6% of total alkaloid content", "paynantheine": "up to 8% of total alkaloid content"}, "bioavailability_notes": "Bioactive alkaloids like mitragynine have variable bioavailability due to factors like individual metabolism and preparation method. Traditional preparation methods may affect nutrient and compound absorption."}

Preparation & Dosage

No clinically studied dosage ranges exist for kratom in any form, as human clinical trials are absent. Alkaloid content varies significantly by strain and source (mitragynine ranges from 12-66% of total alkaloids). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Valerian root, Kava, Ashwagandha, Rhodiola, Turmeric

Safety & Interactions

Common side effects include nausea, constipation, dry mouth, and potential for dependence with regular use. Kratom may interact dangerously with CNS depressants, increasing respiratory depression risk, and can potentiate effects of other opioids. The FDA has issued warnings about contaminated products and potential liver toxicity with chronic use. Pregnancy and breastfeeding safety data is insufficient, with case reports of neonatal withdrawal syndrome.